MHRA approves zanidatamab (Ziihera) for the treatment of biliary tract cancer
Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said: “Zanidatamab provides a new treatment option for adults with advanced biliary tract cancer whose disease has high levels of HER2 and has progressed following previous treatment. This approval reflects the MHRA’s commitment to ensuring patients can access safe and effective medicines where there is an unmet clinical need. As with all approved medicines, we will continue to monitor the safety and effectiveness of zanidatamab as it is used more widely.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.